Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://www.ncbi.nlm.nih.gov/pubmed/31426590
http://dx.doi.org/10.3390/cancers11081203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://www.ncbi.nlm.nih.gov/pubmed/31426590
http://dx.doi.org/10.3390/cancers11081203

Ejemplares similares